MX1 and neoplasm: At necropsy, combination approaches inhibited MX1 ex vivo primary tumour volumes by 79.9% (P < 0.0001), 75.5% (P = 0.0001), 71.7% (P = 0.002), by the conc.T + C., seq.C→T, and seq.T→C strategies, respectively, in comparison to control (Fig. 4e, f).